What's Going On With Intensity Therapeutics Stock Friday?
Intensity Therapeutics, Inc. shares are tumbling on Friday following the announcement of a 1-for-25 reverse stock split to increase the per-share trading price and comply with Nasdaq listing requirements.
The stock’s decline comes as broader markets are experiencing gains, with the S&P 500 up 0.24% and the Nasdaq rising 0.29%.
The reverse stock split, approved by shareholders in October 2025, is set to take effect at 4:01 p.m. Eastern Time on February 18, 2026, with trading on a post-split adjusted basis beginning on February 19, 2026. This move will reduce the number of outstanding shares from approximately 63.3 million to about 2.5 million, which is expected to help the company regain compliance with Nasdaq’s minimum bid price requirement.
In addition to the split, Intensity Therapeutics is focused on its lead product candidate, INT230-6, which is designed for direct intratumoral injection.
The company aims to leverage its proprietary DfuseRx technology to enhance the effectiveness of cancer therapies.
The broader market is experiencing positive momentum, with the Technology sector gaining 1.47% today. Despite this, Intensity Therapeutics’ stock is down, indicating that company-specific factors are influencing its performance.
Technical Analysis
The stock is currently trading 30.8% below its 20-day simple moving average (SMA) and 36.1% below its 50-day SMA, indicating significant weakness in its short-term trend.
Over the past 12 months, shares have decreased by 87.94%, and they are positioned closer to their 52-week lows than highs, suggesting ongoing challenges for the company.
The RSI is at 46.41, which is considered neutral territory, while the MACD is above its signal line, indicating a potential bullish signal. The combination of neutral RSI and bullish MACD suggests mixed momentum for the stock.
- Key Resistance: 50 cents
- Key Support: 20 cents
Earnings Outlook
Looking further out, the next major catalyst for the stock arrives with the March 12, 2026, earnings report.
- EPS Estimate: Loss of 5 cents (Up from Loss of 22 cents YoY)
- Revenue Estimate: $0.00 M
INTS Price Action: Intensity Therapeutics shares were down 26.70% at $0.27 at the time of publication on Friday. The stock is near its 52-week low of $0.18.
Photo by jittawit21 via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Wall Street giants’ trading operations show a tale of two extremes: JPMorgan (JPM.US) expects a surge in Q3 performance, while Bank of America (BAC.US) warns of a slowdown
JPMorgan predicts that trading and investment banking income will see double-digit growth in Q3, triggering a rebound in its stock price. Previously, Bank of America warned of flat revenue due to a pullback in financing, leading to a sell-off in the sector.
Trillion-dollar defense budget in sight, Guggenheim strongly recommends defense stocks, L3Harris Technologies (LHX.US) is the top large-cap pick
Guggenheim Securities recently initiated coverage of 22 aerospace and defense companies, with an overall positive outlook on defense contractors and aircraft manufacturers, but a cautious attitude toward commercial aviation aftermarket suppliers.
Tokenized funds expand across chains, yet liquidity remains fragmented – Why?
Japan Reportedly Plans to Double Defense Spending to 3.5% of GDP, Ministry of Defense Denies, Yet Japanese Bond Yields Hit 30-Year High
According to reports, Japanese defense officials have expressed their willingness to significantly increase defense spending during meetings with the United States. One proposal is to raise defense spending to 3.5% of GDP within ten years, while another, lower target is 3%. Japanese officials previously stated that this fiscal year's defense and related expenditures are approximately $68.8 billion, equivalent to about 1.9% of Japan's nominal GDP in 2022.
Crypto prices
More
